Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study
| Autor: | Ivan Marquez-Rodas, Purificación Martínez de Prado, Elia Samaniego, Lorenzo Alonso, Rafael López Castro, María Quindós, Luis de la Cruz-Merino, Enrique Espinosa, Guillermo Lopez-Vivanco, Rafael López, Pablo Cerezuela, Vicente Guillem, Kendall Stevinson, Virtudes Soriano, Salvador Martín-Algarra, Alfonso Berrocal, Ainara Soria, Patricia del Barrio, Rodrigo Díaz-Beveridge, Teresa Puertolas, M.V. Tornamira, Josep Malvehy, Ana Isabel Ballesteros, Isabel Palacio |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult Male Cancer Research medicine.medical_specialty Population adjuvant treatment Alpha interferon Dermatology Neutropenia Interferon alpha-2 compliance Cohort Studies 03 medical and health sciences Young Adult 0302 clinical medicine Internal medicine melanoma Medicine Humans tolerability education Melanoma Survival analysis Aged Retrospective Studies Aged 80 and over education.field_of_study business.industry Interferon-alpha Retrospective cohort study Middle Aged ORIGINAL ARTICLES: Clinical research medicine.disease Survival Analysis Surgery Clinical trial Regimen 030104 developmental biology interferon-α2b Oncology Chemotherapy Adjuvant 030220 oncology & carcinogenesis Female business Cohort study |
| Zdroj: | Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid Melanoma Research |
| Popis: | Adjuvant interferon-α2b (IFN-α2b) has been studied extensively in clinical trials, but there have been few studies of real-world use. The aim of this study is to describe the IFN-α2b real-world patterns in patients with high-risk melanoma in Spain. This was a retrospective and multicentre chart review study of an unselected cohort of patients with melanoma at high risk for relapse (stage IIB/IIC/III) treated with IFN-α2b. Patterns were assessed in terms of dose and compliance to planned treatment. A survival analysis was carried out for the full population and according to Kirkwood scheme compliance and the presence of ulceration. Of 327 patients treated with IFN-α2b, 318 received a high-dose regimen following the standard Kirkwood scheme; thus, patterns are described for this regimen. A total of 121 (38%) and 88 (28%) patients had at least one dose reduction during the induction and maintenance phases, respectively. Dose delay was required in fewer than 10% of patients. A total of 78, 40 and 38% of the patients completed the induction phase, maintenance phase and completed treatment, respectively. The median progression-free and overall survival for the full population were 3.2 and 10.5 years, respectively. There were no differences in progression-free survival and overall survival according to Kirkwood scheme compliance and the presence of ulceration. The most frequent adverse events were neutropenia (31%) and fatigue (30%). High-dose IFN-α2b is the most frequently used regimen in Spain as an adjuvant systemic treatment for high-risk melanoma. Despite poor compliance, in this retrospective study, IFN-α2b treatment provided a benefit consistent with that described previously. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|